These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35960946)

  • 21. Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014.
    Fan W; Philip S; Granowitz C; Toth PP; Wong ND
    Diabetes Care; 2019 Dec; 42(12):2307-2314. PubMed ID: 31575639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of Lipid Levels and Cardiovascular Disease in HIV-Infected Individuals: Just Give Them a Statin?
    Stein JH
    Top Antivir Med; 2016 Dec-2017 Jan; 23(5):169-73. PubMed ID: 27398770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statin therapy for young adults: A long-term investment worth considering.
    Miedema MD; Nauffal VD; Singh A; Blankstein R
    Trends Cardiovasc Med; 2020 Jan; 30(1):48-53. PubMed ID: 30808553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of statins in the setting of HIV infection.
    Eckard AR; McComsey GA
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):305-12. PubMed ID: 26126687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary.
    Handelsman Y; Jellinger PS; Guerin CK; Bloomgarden ZT; Brinton EA; Budoff MJ; Davidson MH; Einhorn D; Fazio S; Fonseca VA; Garber AJ; Grunberger G; Krauss RM; Mechanick JI; Rosenblit PD; Smith DA; Wyne KL
    Endocr Pract; 2020 Oct; 26(10):1196-1224. PubMed ID: 33471721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dyslipidemias and statins: from guidelines to clinical practice. An updated review of the literature].
    Lucchi T; Vergani C
    G Ital Cardiol (Rome); 2014 Mar; 15(3):149-60. PubMed ID: 24770428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease.
    Zhao Y; Xiang P; Coll B; López JAG; Wong ND
    J Diabetes Complications; 2021 Mar; 35(3):107767. PubMed ID: 33168394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New and Emerging Therapies for Dyslipidemia.
    Zambon A; Averna M; D'Erasmo L; Arca M; Catapano A
    Endocrinol Metab Clin North Am; 2022 Sep; 51(3):635-653. PubMed ID: 35963633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges.
    Ahmed MH; Al-Atta A; Hamad MA
    Expert Opin Pharmacother; 2012 Sep; 13(13):1901-9. PubMed ID: 22770622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment and Low-Density Lipoprotein Cholesterol Management in Patients Diagnosed With Clinical Atherosclerotic Cardiovascular Disease in Alberta.
    Chen G; Farris MS; Cowling T; Colgan SM; Xiang P; Pericleous L; Rogoza RM; Tai MH; Anderson T
    Can J Cardiol; 2019 Jul; 35(7):884-891. PubMed ID: 31292087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dyslipidemia in Human Immunodeficiency Virus Disease: JACC Review Topic of the Week.
    Kalra DK; Vorla M; Michos ED; Agarwala A; Virani S; Duell PB; Raal FJ
    J Am Coll Cardiol; 2023 Jul; 82(2):171-181. PubMed ID: 37407116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan.
    Olufade T; Zhou S; Anzalone D; Kern DM; Tunceli O; Cziraky MJ; Willey VJ
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28473405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LDL as a therapeutic target.
    Díaz Rodríguez Á; Mantilla Morató T
    Clin Investig Arterioscler; 2022; 34(5):271-284. PubMed ID: 35339296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LDL as a therapeutic objective.
    Díaz Rodríguez Á; Mantilla Morató T
    Clin Investig Arterioscler; 2019 Dec; 31 Suppl 2():1-15. PubMed ID: 31813617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease-Real-world experience within a large integrated health care system: The IMPRES study.
    Anderson JL; Knowlton KU; May HT; Bair TL; Armstrong SO; Lappé DL; Muhlestein JB
    J Clin Lipidol; 2018; 12(4):1008-1018.e1. PubMed ID: 29703626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach.
    deFilippi C; Toribio M; Wong LP; Sadreyev R; Grundberg I; Fitch KV; Zanni MV; Lo J; Sponseller CA; Sprecher E; Rashidi N; Thompson MA; Cagliero D; Aberg JA; Braun LR; Stanley TL; Lee H; Grinspoon SK
    J Infect Dis; 2020 Aug; 222(6):929-939. PubMed ID: 32310273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ; Zamorano JL; Parhofer KG
    Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China.
    Lu Y; Zhang H; Lu J; Ding Q; Li X; Wang X; Sun D; Tan L; Mu L; Liu J; Feng F; Yang H; Zhao H; Schulz WL; Krumholz HM; Pan X; Li J;
    JAMA Netw Open; 2021 Sep; 4(9):e2127573. PubMed ID: 34586366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.